Thursday 7 May, 2026
Introduction: Tuberculosis (TB) remains a leading cause of death from a single infectious agent worldwide[1]. Efforts in shortening anti-TB therapy…
Read morePoster: Drug/Disease Modelling - Infection
ON THE USE OF TECOVIRIMAT FOR MPXV INFECTIONS: WHY DO WE NOT SEE SHORTENED TIMES TO VIRAL CLEARANCE IN TREATED PATIENTS?
Thursday 7 May, 2026
Introduction: Before 2022, mpox (formerly known as `monkeypox’) was primarily circulating in endemic areas (West and Central Africa) with sporadic…
Read moreDevelopment of an In-Silico Platform to Explore HIV Incidence Across Different Regions and Its Application to PrEP Clinical Trials for Treatment Design and Optimization
Thursday 7 May, 2026
Introduction. Human immunodeficiency virus (HIV) remains a major global public health challenge, affecting millions worldwide, with the highest prevalence in…
Read moreA PROOF-OF-CONCEPT MECHANISTIC, SYSTEM-BASED FRAMEWORK INTEGRATING HUMAN CYTOKINES, GRANULOPOIESIS, ANTIMICROBIAL PHARMACOKINETICS, AND IN VITRO TIME-KILL EXPERIMENTS FOR HOST – PATHOGEN – ANTIMICROBIAL INTERACTIONS
Thursday 7 May, 2026
Objectives: The continued spread of antimicrobial resistance demands an antibiotic development paradigm that explicitly accounts for the host immune response….
Read moreSemi-mechanistic translational PK/PD modelling to support human dose selection of DNDI-6174 in cutaneous leishmaniasis
Thursday 7 May, 2026
Introduction: Preclinical efficacy models that recapitulate Leishmania parasite infection and treatment response can play a key role in developing much-needed…
Read morePRECLINICAL-TO-CLINICAL PREDICTIONS OF PHASE 2B CLINICAL TRIAL EFFICACY IN TUBERCULOSIS THROUGH BACK-TRANSLATIONAL MODELING OF RIFAPENTINE-CONTAINING REGIMENS
Thursday 7 May, 2026
Objectives: Tuberculosis (TB) remains the leading cause of infectious disease mortality worldwide [1]. The development of improved and shorter treatment…
Read moreMINIMAL-PBPK URINARY MODEL AND FRAMEWORK FOR INVESTIGATION OF NITROFURANTOIN, CIPROFLOXACIN AND FOSFOMYCIN EFFECT ON ESCHERICHIA COLI IN MICROFLUIDIC-BASED HOLLOW FIBER INFECTION MODEL
Thursday 7 May, 2026
INTRODUCTION Antimicrobial resistance continues to rise globally [1], yet research and development in anti‑infective therapeutics face persistent hurdles, reflected in…
Read morePILOT STUDY AIMING TO QUANTIFY VIABLE BUT NON- OR SLOWLY REPLICATING MYCOBACTERIUM TUBERCULOSIS BACTERIA
Thursday 7 May, 2026
Objectives Mycobacterium tuberculosis (Mtb) can exist in different metabolic states, ranging from fast-growing populations to viable but non- or slowly…
Read morePopulation Pharmacokinetics of Dolutegravir with Daily Rifapentine for HIV-associated Tuberculosis
Thursday 7 May, 2026
Objectives: Dolutegravir remains a key component of first-line antiretroviral therapy in settings with a high burden of HIV and tuberculosis…
Read more(Val)ganciclovir against cytomegalovirus: Are we currently dosing too low?
Thursday 7 May, 2026
Objectives Cytomegalovirus (CMV) is a human herpesvirus that causes significant mortality and morbidity in immunocompromised patients (1). The first-line drug,…
Read more